Astellas Pharma Inc.

TSE:4503 Stock Report

Market Cap: JP¥2.8t

Astellas Pharma Past Earnings Performance

Past criteria checks 3/6

Astellas Pharma's earnings have been declining at an average annual rate of -31.6%, while the Pharmaceuticals industry saw earnings growing at 4.3% annually. Revenues have been growing at an average rate of 6.5% per year. Astellas Pharma's return on equity is 3.6%, and it has net margins of 3.1%.

Key information

-31.6%

Earnings growth rate

-30.7%

EPS growth rate

Pharmaceuticals Industry Growth3.4%
Revenue growth rate6.5%
Return on equity3.6%
Net Margin3.1%
Last Earnings Update30 Sep 2024

Recent past performance updates

Astellas Pharma's (TSE:4503) Earnings May Just Be The Starting Point

Nov 06
Astellas Pharma's (TSE:4503) Earnings May Just Be The Starting Point

Recent updates

Astellas Pharma (TSE:4503) Will Pay A Dividend Of ¥37.00

Dec 04
Astellas Pharma (TSE:4503) Will Pay A Dividend Of ¥37.00

Astellas Pharma's (TSE:4503) Earnings May Just Be The Starting Point

Nov 06
Astellas Pharma's (TSE:4503) Earnings May Just Be The Starting Point

Astellas Pharma Inc. (TSE:4503) Just Released Its Half-Yearly Earnings: Here's What Analysts Think

Nov 01
Astellas Pharma Inc. (TSE:4503) Just Released Its Half-Yearly Earnings: Here's What Analysts Think

Astellas Pharma Inc.'s (TSE:4503) Earnings Haven't Escaped The Attention Of Investors

Oct 15
Astellas Pharma Inc.'s (TSE:4503) Earnings Haven't Escaped The Attention Of Investors

Astellas Pharma (TSE:4503) Has Announced That It Will Be Increasing Its Dividend To ¥37.00

Sep 24
Astellas Pharma (TSE:4503) Has Announced That It Will Be Increasing Its Dividend To ¥37.00

Astellas Pharma (TSE:4503) Has Announced That It Will Be Increasing Its Dividend To ¥37.00

Sep 03
Astellas Pharma (TSE:4503) Has Announced That It Will Be Increasing Its Dividend To ¥37.00

Astellas Pharma (TSE:4503) Has Announced That It Will Be Increasing Its Dividend To ¥37.00

Aug 20
Astellas Pharma (TSE:4503) Has Announced That It Will Be Increasing Its Dividend To ¥37.00

Earnings Beat: Astellas Pharma Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Aug 04
Earnings Beat: Astellas Pharma Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Astellas Pharma's (TSE:4503) Shareholders Will Receive A Bigger Dividend Than Last Year

Jul 26
Astellas Pharma's (TSE:4503) Shareholders Will Receive A Bigger Dividend Than Last Year

Astellas Pharma (TSE:4503) Is Paying Out A Larger Dividend Than Last Year

Jul 11
Astellas Pharma (TSE:4503) Is Paying Out A Larger Dividend Than Last Year

Is Astellas Pharma (TSE:4503) A Risky Investment?

Jun 14
Is Astellas Pharma (TSE:4503) A Risky Investment?

Astellas Pharma's (TSE:4503) Soft Earnings Are Actually Better Than They Appear

May 02
Astellas Pharma's (TSE:4503) Soft Earnings Are Actually Better Than They Appear

Astellas Pharma Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Apr 29
Astellas Pharma Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Why We're Not Concerned About Astellas Pharma Inc.'s (TSE:4503) Share Price

Feb 29
Why We're Not Concerned About Astellas Pharma Inc.'s (TSE:4503) Share Price

Revenue & Expenses Breakdown

How Astellas Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

TSE:4503 Revenue, expenses and earnings (JPY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,772,15554,746799,059324,570
30 Jun 241,701,80621,519775,191316,416
31 Mar 241,603,67217,045740,110294,187
31 Dec 231,543,3244,198706,256286,410
30 Sep 231,523,57238,090669,778278,898
30 Jun 231,511,818107,031645,058266,713
31 Mar 231,518,61998,714630,272276,128
31 Dec 221,468,235136,430613,397274,414
30 Sep 221,406,682148,911586,290266,127
30 Jun 221,351,811118,211565,127261,704
31 Mar 221,296,163124,086548,840246,010
31 Dec 211,300,914120,167547,692233,316
30 Sep 211,285,714119,360532,687231,849
30 Jun 211,268,702100,863520,649225,514
31 Mar 211,249,528120,589504,316224,489
31 Dec 201,253,215138,307508,764233,293
30 Sep 201,265,853139,722515,363230,952
30 Jun 201,273,678187,306502,601228,007
31 Mar 201,300,843195,411499,295224,226
31 Dec 191,289,855220,751488,054218,477
30 Sep 191,309,722246,925484,800214,090
30 Jun 191,311,397226,224494,845210,057
31 Mar 191,306,348222,265490,263208,682
31 Dec 181,305,901213,600484,099209,117
30 Sep 181,307,658186,429481,546212,867
30 Jun 181,306,830176,770478,883216,436
31 Mar 181,300,316164,679478,330220,781
31 Dec 171,305,521182,515484,126221,463
30 Sep 171,299,746185,754478,249215,938
30 Jun 171,296,484194,556471,227213,584
31 Mar 171,311,665218,701470,777208,129
31 Dec 161,312,627207,940474,335208,958
30 Sep 161,336,878205,818481,460213,295
30 Jun 161,366,799215,678493,582220,707
31 Mar 161,372,706193,687500,359225,665
31 Dec 151,360,153185,659497,984223,590
30 Sep 151,340,307168,805490,493221,608
30 Jun 151,295,761144,617474,276214,931
31 Mar 151,247,259135,856452,522206,594
31 Dec 141,205,276124,154251,755339,460
30 Sep 141,177,660112,663296,063288,487
30 Jun 141,159,218104,614343,246239,103
31 Mar 141,139,90990,874397,018191,460
31 Dec 131,137,82479,679433,675181,955

Quality Earnings: 4503 has a large one-off loss of ¥103.9B impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: 4503's current net profit margins (3.1%) are higher than last year (2.5%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 4503's earnings have declined by 31.6% per year over the past 5 years.

Accelerating Growth: 4503's earnings growth over the past year (43.7%) exceeds its 5-year average (-31.6% per year).

Earnings vs Industry: 4503 earnings growth over the past year (43.7%) exceeded the Pharmaceuticals industry 12.2%.

Return on Equity

High ROE: 4503's Return on Equity (3.6%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 20:33
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Astellas Pharma Inc. is covered by 31 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Atsushi SekiBarclays
Koichi MameganoBofA Global Research
Hazim BahariCFRA Equity Research